Myocardial Prdx1 overexpression via AAV9-Prdx1 injection significantly inhibited pressure-overload-induced pathological cardiac remodeling post-TAC, including myocardial hypertrophy, dysfunction, fibrosis, inflammation, and oxidative stress compared with control groups. Here, PRDX1 is linked to cardiac hypertrophy.